Study of NST-6179 in Healthy Subjects

NorthSea Therapeutics

Status and phase: Completed; Phase 1

Conditions: Short Bowel Syndrome; Parenteral Nutrition Associated Liver Disease

Treatments: Drug: Placebo; Drug: NST 6179

Study type: Interventional

Funder types: Industry

Identifiers

NCT05181085

NST-6179-01

Details and patient eligibility

About

A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.

Enrollment: 70 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Males or females, of any race, between 18 and 65 years of age, inclusive.
2. Body mass index between 18.0 and 32.0 kg/m^2, inclusive.
3. In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening and/or check in as assessed by the investigator (or designee).
4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions

Exclusion Criteria (additional criteria available):

1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).

2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).

3. Any of the following:

   1. QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 ms confirmed by repeat measurement.
   2. QRS duration > 110 ms confirmed by repeat measurement.
   3. PR interval > 220 ms confirmed by repeat measurement.
   4. findings which would make QTc measurements difficult or QTc data uninterpretable.
   5. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, family history of long QT syndrome).

4. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).

5. Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee).

6. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing.

7. Vegetarians, vegans, and/or unable to consume the high fat breakfast (subjects participating in a food effect evaluation only).

8. History of alcoholism or drug/chemical abuse within 2 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

70 participants in 2 patient groups, including a placebo group

NST 6179

Active Comparator group

Description:

double blind, single ascending and multiple ascending dose, sequential group design

Treatment:

Drug: NST 6179

Placebo

Placebo Comparator group

Description:

matched placebo arm

Treatment:

Drug: Placebo